Figures & data
Figure 1. Cohort development in Wilson’s disease study with and without the SARS-CoV-2 vaccination.
This figure shows 23 patients refused to participate, and 28 were excluded due to severe dysarthria and cognitive impairment, which prevented them from cooperating. A total of 554 WD patients were included in this study.
Table 1. Patients’ characteristics and vaccination status.
Figure 2. Population distribution and regional vaccination rate of WD patients (color).
This figure shows the regional distribution of the participants included in the study. The participants covered 4 municipalities, 22 provinces, and 5 autonomous regions in China. Due to the geographical location of the study site and the epidemic, the most distributed regions were Anhui (n=164, 29.6%), Jiangsu (n=68, 12.3%), and Shandong (n=56, 10.1%). The vaccination rates for WD patients varied.
Figure 3. The subjective reason for not vaccinating (color).
Through the questionnaire survey, the subjective reason why patients did not receive the vaccine were the advice of the medical center (n=83,44.6%), fear of worsening WD symptoms (n=63, 33.9%), and doubts about the effectiveness and safety of the vaccine (n=40, 21.5%).
Table 2. Analysis of confounding factors and multi-factors in vaccination combination group without vaccination.
Figure 4. Association of vaccination status with increased UWDRS score in patients with Wilson’s disease (color).
Logistic regression analysis showed that vaccination against SARS-CoV-2 was not significantly associated with increased scores on the UWDRS (OR=0.924, 95% CI: 0.336–2.540, P=0.879), hepatic subscale (OR=0.170, 95% CI: 0.148–3.027, P=0.603), neurological subscale (OR=1.322, 95% CI: 0.219–7.984, P=0.761), or psychiatric subscale (OR=1.011, 95% CI: 0.183–5.571, P=0.990). Values are the number (%) for categorical variables.
Table 3. Impact of vaccination on UWDRS score.
Table 4. Adverse events following COVID-19 vaccination in WD patients.